
Please try another search
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company’s lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was founded in 1996 and is based in Carlsbad, California.
Name | Age | Since | Title |
---|---|---|---|
Campbell Becher | 53 | 2024 | President & Independent Director |
Wayne D. Klohs | - | 2022 | Chair of Scientific Advisory Board |
Robert Bradley Lim | 31 | 2024 | Independent Director |
Graydon Bensler | 33 | 2024 | Independent Director |
Anthony W. Tolcher | - | 2022 | Member of Scientific Advisory Board |
Christopher Slapak | 66 | 2022 | Member of Scientific Advisory Board |
Patricia M. LoRusso | - | 2022 | Member of Scientific Advisory Board |
Michael S. Gordon | - | 2022 | Member of Scientific Advisory Board |
Kevin A. Richardson | 57 | 2024 | Interim CEO, Interim CFO, Chief Accounting Officer & Chairman of the Board |
Lillian L. Siu | - | 2022 | Member of Scientific Advisory Board |
Stephen Neidle | - | 2022 | Member of Scientific Advisory Board |
Cody Price | 46 | 2024 | Independent Director |
Robert W. Campbell Becher | 54 | 2024 | President & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review